BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement

January 27, 2021 15:14:11

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced that it has entered into a definitive agreement to acquire Upright Technologies Ltd., a digital musculoskeletal (“MSK”) company; the acquisition will be in the form of a stock transaction. The acquisition is designed to expand DarioHealth’s multi-condition platform into the $213 billion musculoskeletal market and create one of the most comprehensive digital health platforms. The move also brings together complementary companies with industry-leading consumer engagement and clinical outcomes. In addition, DRIO has entered into definitive agreements with a group of health-care institutional investors to raise $70 million through a private placement. That financing includes several leading health-care focused institutional investors such as Nantahala Capital Management LLC, Perceptive Advisors, Driehaus Capital Management, Farallon Capital Management, Pura Vida Investments, and others. “I am very pleased to be able to achieve this milestone and expect that MSK will be a meaningful growth driver for our company for years to come,” said Dario CEO Erez Raphael in the press release. “We are committed to delivering the industry’s most comprehensive, clinically proven solution for the management of chronic conditions, and the addition of Upright, which is an expansion of our core competency, represents a significant step toward that goal. With similar approaches to building highly engaging and clinically effective products and similar cultures, I anticipate a rapid and seamless integration.”

To view the full press release, visit https://ibn.fm/VtZff

About DarioHealth Corp.

DarioHealth is a leading global, digital-therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market; its highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork